Therapy News and Research

RSS

Janssen receives FDA Priority Review for bedaquiline NDA to treat MDR-TB

Janssen Research & Development, LLC (Janssen) announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the New Drug Application (NDA) for bedaquiline (TMC207) to treat pulmonary, multi-drug resistant tuberculosis (MDR-TB) in adults as part of combination therapy.

6 Sep 2012

Kinetic Concepts launches Skin IQ 1000 MCM to help prevent and treat stage I-IV pressure ulcers

Kinetic Concepts, Inc. (KCI) announced today the U.S. launch of the Skin IQ 1000 Microclimate Manager (MCM) by its Therapeutic Support Systems (TSS) business.

6 Sep 2012

Corticosteroids needed after DALK to avert stromal rejection

Like those undergoing penetrating keratoplasty, patients treated with deep anterior lamellar keratoplasty may benefit from taking postoperative corticosteroids to prevent stromal rejection, report US researchers.

5 Sep 2012

Voice therapy should be offered to more thyroidectomy patients

Voice problems following surgery to remove the thyroid gland are a common problem reported by patients, but only a minority are offered voice therapy, show results from a US study.

5 Sep 2012

On-the-spot test aids postsurgical coagulopathy management

Point-of-care thromboelastometric and aggregometric testing helps to reduce exposure to allogenic blood products in patients with coagulopathy after cardiac surgery, a randomized trial shows.

5 Sep 2012

Biomarker predicts temsirolimus benefit in renal cancer

In patients with metastatic renal cell carcinoma, the biomarker serum lactate dehydrogenase is both prognostic for survival and predictive for the survival benefit conferred by the TORC1 inhibitor temsirolimus, research shows.

5 Sep 2012

Real-time prescription system reduces inappropriate prescribing of medications

A centralized prescription network providing real-time information to pharmacists in British Columbia, Canada, resulted in dramatic reductions in inappropriate prescriptions for opioid analgesics and benzodiazepines, widely used and potentially addictive drugs. The findings are reported in a study in CMAJ (Canadian Medical Association Journal).

5 Sep 2012

People with generalized anxiety disorder have weak brain connections

A new University of Wisconsin-Madison imaging study shows the brains of people with generalized anxiety disorder (GAD) have weaker connections between a brain structure that controls emotional response and the amygdala, which suggests the brain's "panic button" may stay on due to lack of regulation.

5 Sep 2012

NeuroSigma's external Trigeminal Nerve Stimulation system awarded CE Certification

NeuroSigma, Inc., a Los Angeles-based medical device company, announced today that it received CE Certification for its external Trigeminal Nerve Stimulation (eTNS) system, called the Monarch, for the adjunctive treatment of epilepsy and major depressive disorder, for adults and children 9 years and older.

5 Sep 2012

Sleep apnoea severity associated with increased cancer mortality

Sleep apnoea severity has been associated with increased cancer mortality in a new study.

5 Sep 2012

Zalicus commences first of two Z160 Phase 2a clinical studies for chronic neuropathic pain

Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced that it has initiated the first of two Phase 2a clinical studies with Z160, its first-in-class, oral, state-dependent, selective N-type calcium channel blocker for the treatment of chronic neuropathic pain indications.

5 Sep 2012

ARGO Medical, Cyclone Technologies announce availability of ReWalk exoskeleton system

5 Sep 2012

Baxter seeks FDA BLA approval for BAX 326 rFIX protein to treat hemophilia B

Baxter International Inc. today announced that the company has submitted a biologics license application to the United States Food and Drug Administration for approval of BAX 326, a recombinant factor IX (rFIX) protein being investigated for the treatment and prophylaxis of bleeding episodes for patients over 12 years of age with hemophilia B.

From Baxter International Inc. 5 Sep 2012

FDA approves Bosulif to treat chronic myelogenous leukemia

The U.S. Food and Drug Administration today approved Bosulif (bosutinib) to treat chronic myelogenous leukemia (CML), a blood and bone marrow disease that usually affects older adults.

5 Sep 2012

Scientists identify master regulator essential for progression and relapse of deadly brain cancer

A*STAR scientists have identified a biomarker of the most lethal form of brain tumours in adults- glioblastoma multiforme. The scientists found that by targeting this biomarker and depleting it with a potential drug, they were able to prevent the progression and relapse of the brain tumour.

5 Sep 2012

IPS examines challenges to slowing spread of HIV in Eastern Europe, Central Asia

"Despite pledges from governments across Eastern Europe and Central Asia to fight HIV/AIDS -- one of the eight Millennium Development Goals -- the region has the world's fastest-growing HIV epidemic," Inter Press Service reports in an article examining challenges to stemming the spread of the disease, particularly among injection drug users.

5 Sep 2012

AlloCure commences AC607 Phase 2 clinical trial for acute kidney injury

AlloCure, Inc. today announced that it has initiated a phase 2 clinical trial of AC607, the company's mesenchymal stem cell therapy, as a potential treatment for acute kidney injury.

5 Sep 2012

Avanir initiates enrollment in AVP-923 Phase II clinical trial for treatment of agitation in AD patients

Avanir Pharmaceuticals, Inc. today announced the enrollment of the first patient in study AVR-131. The study is a Phase II clinical trial investigating the use of AVP-923 for the treatment of agitation in patients with Alzheimer's disease.

5 Sep 2012

EC grants European market authorization for Revestive to treat short bowel syndrome

Takeda Pharmaceutical Company Limited and NPS Pharmaceuticals, Inc., jointly announced today that the European Commission has granted European market authorization for the medicinal product teduglutide (trade name in Europe: Revestive) as a once-daily treatment for adult patients with short bowel syndrome.

5 Sep 2012

Exoskeleton technology now available to take home

Exoskeleton technology leader, ARGO Medical Technologies, along with mobility solutions provider, Cyclone Technologies, announced today that Claire Lomas has become the first person to take home an exoskeleton system for personal use. Claire demonstrated her personal ReWalk™ at the annual International Spinal Cord Society (ISCoS) meeting held at the Queen Elizabeth II Conference Center.

5 Sep 2012

Therapy News and Research

Janssen receives FDA Priority Review for bedaquiline NDA to treat MDR-TB

Kinetic Concepts launches Skin IQ 1000 MCM to help prevent and treat stage I-IV pressure ulcers

Corticosteroids needed after DALK to avert stromal rejection

Voice therapy should be offered to more thyroidectomy patients

On-the-spot test aids postsurgical coagulopathy management

Biomarker predicts temsirolimus benefit in renal cancer

Real-time prescription system reduces inappropriate prescribing of medications

People with generalized anxiety disorder have weak brain connections

NeuroSigma's external Trigeminal Nerve Stimulation system awarded CE Certification

Sleep apnoea severity associated with increased cancer mortality

Zalicus commences first of two Z160 Phase 2a clinical studies for chronic neuropathic pain

ARGO Medical, Cyclone Technologies announce availability of ReWalk exoskeleton system

Baxter seeks FDA BLA approval for BAX 326 rFIX protein to treat hemophilia B

FDA approves Bosulif to treat chronic myelogenous leukemia

Scientists identify master regulator essential for progression and relapse of deadly brain cancer

IPS examines challenges to slowing spread of HIV in Eastern Europe, Central Asia

AlloCure commences AC607 Phase 2 clinical trial for acute kidney injury

Avanir initiates enrollment in AVP-923 Phase II clinical trial for treatment of agitation in AD patients

EC grants European market authorization for Revestive to treat short bowel syndrome

Exoskeleton technology now available to take home

Industry Focus eBook - Cell biology (5th edition) eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News